On this page
Evidence dossier
The report behind the claim
The study reported reduced vascular and multiorgan disturbance after treatment. An emergency pressure syndrome is not a general digestive-health or bloating trial.
Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats.
- Design
- Experimental animal investigation with the intervention and outcomes specified in the indexed abstract.
- Participants or model
- Anesthetized rats with experimentally elevated abdominal pressure
- Endpoint
- Pressure, circulation, thrombosis and organ injury
- Finding on record
- The study reported reduced vascular and multiorgan disturbance after treatment.
- Limits of inference
- An emergency pressure syndrome is not a general digestive-health or bloating trial.
The experiment in view
The study used anesthetized rats with experimentally elevated abdominal pressure. Its principal measures were pressure, circulation, thrombosis and organ injury. The study reported reduced vascular and multiorgan disturbance after treatment.
Reading the result closely
A large collection of outcomes can all follow one initiating insult. That breadth should not be counted as proof for many unrelated indications. The pressure protocol, anesthesia and short observation period are essential limits when considering the authors' wider interpretation.
The boundary of the finding
An emergency pressure syndrome is not a general digestive-health or bloating trial.
Related evidence, kept separate
BPC-157 in a rat liver-inflow clamping model examines vascular, biochemical and multiple-organ injury measures. Here, the measured endpoint was pressure, circulation, thrombosis and organ injury. Those outcomes belong to separate experiments; one is not a replication or a human confirmation of the other. Compare that distinction with the What changes when a BPC-157 paper becomes a sales claim? appraisal.
On the record
The documents supporting this report.